Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects.

Third Rock Ventures Platform Team develops, implements and refines technologyroadmaps for Third Rock Ventures portfolio companies with a focus on the identificationand integration of drug discovery and development technology platforms.

Tango Therapeutics is a new cancer therapeutics company discovering and developing novel medicines designed to target cancer vulnerabilities beyond mutated oncogenes to deliver transformational new therapies for patients. We are going beyond current cancer treatments and targeting unaddressed disease mechanisms to develop transformational new drugs for patients. Powered by genetic data from patient tumors and advances in CRISPR-based target discovery, we are discovering medicines that embrace the complexity of cancer with the bold goal of cures.

Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for kidney disease. Just as the goldfinch was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney disease. At Goldfinch, we’re pioneering a new approach to discover and develop therapeutics that target the molecular basis of kidney disease. Where others see risk, we see opportunity to make an impact and redefine the state of care for patients with kidney disease. We recognize the importance of collaboration, and strive to work alongside patients, clinicians and other partners to empower patients and develop treatments for conditions where no approved therapies exist. We’re looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.

Relay Therapeutics was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities. This leap forward in drug discovery allows Relay Therapeutics to leverage the relationship between protein motion and function, creating opportunities to develop more effective therapies for multiple diseases. Relay's approach combines key technological advances into one integrated drug discovery engine that can effectively enable rational allosteric drug discovery.

Agios Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and inborn errors of metabolism, or IEMs, which are rare genetic metabolic diseases, through scientific leadership in the field of cellular metabolism.

TransForm Pharmaceuticals built proprietary high-throughput (HT) experimentation platforms to screen for better drugs through optimizing form and formulation of active pharmaceutical ingredients (APIs).

SimUtility, Inc. built and operated High Performance Computing (HPC) Online Services (SaaS) for industry leaders in engineering and life sciences.

CambridgeSoft Corporation provided desktop software and enterprise solutions for chemical and biological informatics.

ARIAD Pharmaceuticals is dedicated to developing breakthrough medicines that regulate cell-signaling pathways implicated in cancer.